LALaura Audí

Laura Audí

*This is an algorithmically generated author record based on publicly available information.

Laura Audí has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Long-Term GH Therapy: Epidemiology and Auxologic Outcome

    by L. Audí, A. Gilabert, G. Lloveras, C. Martí-Henneberg, F. Rodríguez-Hierro, E. Vilardell, S. Webb, J. Canela, E. Sedano, E. Vicens-Calvet

    Objectives: Epidemiologic and auxologic characteristics of patients treated with GH during childhood and adolescence and entered in a national registry in Catalonia were studied between 1988 and 1997. At the end of 1997, prevalence was 53.2 treatments/100,000 inhabitants aged 0–14 years. Maximum annual incidence rates were observed in 1990 and 1991 (34.0–35.6 cases/100,000 inhabitants aged 0–14 years). Study Design: Analysis of treatments terminated in 1993 (n = 548) revealed, for the three principal reasons for cessation of treatment (‘near-final height’, ‘adequate height but further growth potential’, and ‘poor growth response’), that males began and ended treatment at older ages with a better auxologic situation in SDS than girls at the beginning and end of therapy in the first two subgroups, with a similar duration of therapy. Severe GH deficiency (GHD) [both multiple pituitary hormone deficiency (MPHD) and the most severe isolated GHD (IGHD-A)] was more frequent in the group ending treatment at ‘near-final height’, whereas cessation of therapy because of ‘poor growth response’ was more frequent in the group with ‘other causes of short stature’ and no demonstrable GHD by routine tests. In the near-final height group, after excluding Turner’s syndrome, MPHD and GHD cases secondary to brain tumors and GH deficiencies associated with malformative syndromes, positive linear correlations were observed between HSDS at the end of treatment and HSDS at the beginning, predicted adult height SDS (PAHSDS) and target height SDS (THSDS). Multiple regression analysis showed that in this group of patients, 41.4% of the variability in HSDS increment can be explained by the equation: HSDS increment = –0.33 + 0.29 THSDS – 0.68 HSDS at the beginning of treatment. Results: The outcome showed a reasonable use of GH, since good-response cases generally continued treatment until final height whereas therapy was suspended in doubtful cases.


  • Clinical and Biochemical Determinants of Bone Metabolism and Bone Mass in Adolescent Female Patients with Anorexia Nervosa

    by Laura Audí, Deisi M Vargas, Miquel Gussinyé, Diego Yeste, Gertrudis Martí, Antonio Carrascosa


    • 13 January 2001
      • Vol. 116  (1) , 6-11

    [Low sensitivity of IGF-I, IGFBP-3 and urinary GH in the diagnosis of growth hormone insufficiency in slowly-growing short-statured boys. Grupo Español de Estudio de la Talla Baja].

    by L Audí, M Antonia Llopis, M Luisa Granada, F Hermoso, J Del Valle, M Dolores Rodríguez-Arnao, J Bel, C Luzuriaga, E Gallego, F Marín, et al.

    The usefulness of IGF-I, IGFBP-3, and the urinary GH excretion in the diagnostic evaluation of growth retardation in boys with short stature was studied. Serum samples from two GH-stimulation tests and two 24-h urine samples were sent to a Central Laboratory to measure serum and urinary GH, serum IGF-I, IGFBP-3 and GHBP, both in absolute and standardized values (Z-score). Short children were classified as growth hormone deficient (GHD) (n = 25), and idiopathic short statured (ISS) (n = 54), on the basis of the peak stimulated GH concentration of < 7.5 microg/l or > or = 7.5 microg/l respectively. A group of 15 normally growing children and adolescents was also included. Height-velocity standard deviation score (HV)-SDS was lower and body mass index higher in GHD than ISS. Standardized IGF-I differed significantly by ANOVA among the three groups (p = 0.001). Multiple stepwise linear regression analysis with HV-SDS as dependent variable showed IGF-I SDS as the best predictor followed by peak GH clonidine response and uGH excretion. ROC curves showed optimum cut-off level for IGF-I SDS as 2.05 (sensitivity: 32%, specificity: 90%) and 1.14 for IGFBP-3 SDS sensitivity: 28%, specificity: 94%). Standardized IGF-I and IGFBP-3 measurements were highly efficient only in diagnosis of severe GHD, but they show low sensitivity for the diagnosis of isolated idiopathic GHD as defined according to the low GH response to stimulation tests.


  • Effects of TGF-?1 on Proliferation and IGFBP-3 Production in a Primary Culture of Human Fetal Epiphyseal Chondrocytes (HFEC)

    by M. Garcia-Ramirez, L. Audi, P. Andaluz, A. Carrascosa

    Proliferation and differentiation of chondrocytes from growth cartilage are modulated by hormones and growth factors, among which TGF-betas have been recognized as some of the more potent regulators although their specific cell effects on cartilage physiology are not fully understood. Primary human fetal epiphyseal chondrocytes (HEFC) constitutively produce TGF-beta1 at different times of culture progression. Treatment of 48-h. serum-deprived semiconfluent HFEC with 0.1-50 ng/ml of TGF-beta1 for 48-h. decreased (3H)Thymidine incorporation by 25-50 % and cell number by 25 %. In addition, IGFBP-3, the main insulin-like bonding protein produced by HFEC, showed a slight increase by TGF-beta1 in culture media. The changes in IGFBP-3 protein levels correlated well with its mRNA, indicating that TGF-beta1 is able to up-regulate IGFBP-3 synthesis in chondrocytes. Nevertheless, the IGFBP-3 accumulation in culture media does not produce a clear growth inhibitory effect on chondrocytes. Thus, we conclude that even though TGF-beta1 is able to up-regulate IGFBP-3, the growth inhibitory action produced by TGF-beta1 is not mediated by IGFBP-3 increase and appears to be mainly a direct TGF-beta1 effect on HFEC.


  • Genetic Determinants of Bone Mass

    by Laura Audí, Marta García-Ramírez, Antonio Carrascosa

    A genetic contribution to bone mass determination was first described in the early 70s. Elucidation of gene contribution to this has since been attempted through studies analyzing associations between bone mass acquisition and/or maintenance and polymorphic variations of several genes. The first to be described was the vitamin D receptor gene (VDR), initially claimed to contribute to almost 75% of the genetic variation in bone mineral density (BMD) in twin and general population studies. Not all of the studies published to date conclude that a clear relationship exists between polymorphic VDR alleles and BMD, and the molecular basis for the VDR gene polymorphisms influence on bone mineralization has not yet been clarified. Since then, other genes with a significant role in bone metabolism such as estradiol receptor, collagen type 1α1, TGF-β1, interleukin-6, calcitonin receptor, α2-HS-glycoprotein, osteocalcin, calcium-sensing receptor, interleukin-1 receptor antagonist, β3-adrenergic receptor, apolipoprotein E, PTH, IGF-I and glucocorticoid receptor have been analyzed. Some polymorphic variations in these genes have been associated in some works with significant differences in BMD, with even more significant contributions when associations of different gene polymorphisms were analyzed. Again, the molecular basis for the contribution of these alleles to bone mass determination has not yet been described. A different approach has been attempted by linkage analysis of loci involved in bone density in pedigrees with low BMD using BMD as a quantitative trait. Recent results do not confirm, in these families, any association with any of the previously reported genes, but rather with other as yet unidentified genes. The genetic contribution to mild variations in the general population, as a result of environmental and endogenous individual influences, probably differs completely from that providing a pathologic BMD.


    • 25 January 1997
      • Vol. 108  (3) , 87-90

    [Adult height, pattern of growth and pubertal development in patients with congenital adrenal hyperplasia, salt losing form].

    by M Gussinyé, N Potau, E Vicens-Calvet, M A Albisu, Diego Yeste, L Ibáñez, L Audí, A Carrascosa

    The height growth pattern in 24 patients with the salt-wasting from of congenital adrenal hyperplasia was retrospectively evaluated from the neonatal period to attainment of adult height. All patients were on mineralcorticoid therapy and received hydrocortisone (mg/m2 body surface and day. Mean +/- SD): 34.53 +/- 8.2 during the first year of life, 22.83 +/- 4.1 from then to the puberty onset and 21.83 +/- 3.6 during puberty. Height was measured every 3-4 months and compared with that of the normal age- and sex-matched controls. Height differences with respect to reference population (M +/- SD) were: +0.38 +/- 0.82 in the neonatal period; -2.21 +/- 1.1 at one year of age; -0.76 +/- 1.25 at three years of age; -0.45 +/- 0.99 at the onset of puberty and -1.34 +/- 0.79 at attainment of adult height. Adult height differed significantly (p < 0.01) from control values and in girls from those of their mothers (p < 0.05). Hyperandrogenism, evaluated through urinary 17-ketosteroids, testosterone, delta 4 androstenedione and DA-S, was not documented during prepuberty and puberty. Our patients showed a lower growth rate than those of the control population during the two periods of higher growth potentiality: the first year of life and puberty, and this results in adult height impairment.


    • 1 June 1996
      • p. 313-24

    Growth hormone secretion assessment in the diagnosis of short stature.

    by L Audí, M L Granada, A Carrascosa

    Growth hormone (GH) secretion assessment in the diagnosis of short stature presents certain problems in relation to the protocols designed for it and the interpretation of results. GH measurement in serum may be accompanied by IGF-I and IGFBP-3 measurements, and in some patients by GHBP measurement. Protocols for evaluating GH response to acute stimuli or spontaneous secretion are tedious, sometimes hazardous and difficult to interpret. This is due to the wide variation in responses observed in normally-growing children, to the age-dependent changes in these parameters and, in the case of GH, to the wide variation in immunoassay results. New techniques able to measure biologically-active GH molecules circulating in blood may help to simplify diagnosis. Severe idiopathic or organic GH deficiency poses no diagnostic problems. GH secretory insufficiency may be diagnosed as partial, idiopathic, isolated GH deficiency or as neurosecretory dysfunction. Clear cut-off values for these diagnoses and the possibility of a transient reversible pathology are not well established. Analysis of large series of children with different diagnoses in whom the growth pattern, either spontaneous or under rhGH treatment, final height and GH secretion re-evaluation at the end of growth were studied will help to clarify GH secretion or action abnormalities in these patients.